Jeyou Pharmaceutical

Shanghai Jeyou Pharmaceutical is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the discovery and development of innovative therapeutics. Spun off as an independent entity from Jiangxi Jemincare Group in 2018, the company focuses on a strategic '3+1' matrix of therapeutic areas including oncology, nephrology, pain, and autoimmune disorders. Its lead candidate, JYB1904 (also known as ozureprubart), is a long-acting anti-IgE monoclonal antibody currently in Phase 2 clinical trials for food allergy and preparing for Phase 3 for chronic spontaneous urticaria. Jeyou maintains a broad pipeline of over 40 research projects, with a significant balance between small-molecule and large-molecule drugs. The company gained global recognition through its strategic licensing agreement with RAPT Therapeutics (later acquired by GSK) for the international development of its flagship anti-IgE program.